Edelris Announces Collaboration With Merck Serono in Fragment Based Drug Discovery
Advertisement
Edelris announced that they have signed collaboration with Merck Serono, a division of Merck KGaA, Darmstadt,Germany, aiming at the delivery of innovative and exclusive chemical entities for Fragment-Based Drug Discovery (FBDD).
"We are pleased to be collaborating again with Merck Serono on cutting-edge discovery technologies," said Dr. Jean-Yves Ortholand, CEO of Edelris. "Edelris has acquired a unique expertise in the synthesis of biorelevant innovative fragments maximizing 3D-diversity. Our platform has been developed to explore targeted or diversified spaces aiming at providing fragments with high potential for molecular interactions" added Dr.Didier Roche, VP Strategy and Innovation at Edelris.